- Biopharmaceutical company Adagio Therapeutics ( NASDAQ: ADGI ) changed its name to Invivyd.
- The company will begin trading under the new ticker symbol IVVD on the Nasdaq Global Market from Sep. 13.
- The new name considers the company's strategy associated with the development and commercialization of antibodies.
- The company has also adopted a new logo and refreshed its corporate website.
- Additionally, ADGI said it has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19. The antibodies include two molecules designated for near-term clinical development in combination as NVD200.
- NVD200 is expected to enter the clinic in Q1 2023.
- Shares were trading +6.09% pre-market.
For further details see:
Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies